A meta-analysis of 49 studies on the use of Viscum album (mistletoe) extract (Iscador) in cancer patients found that adjuvant treatment with Iscador was associated with improved survival outcomes. The pooled hazard ratio was 0.59 (95% CI: 0.53–0.66, p
